BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 234 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 0.15 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $79,289 | +1.5% | 11,199 | +0.9% | 0.00% | 0.0% |
| Q2 2023 | $78,102 | -11.7% | 11,094 | +4.6% | 0.00% | 0.0% |
| Q1 2023 | $88,462 | -27.4% | 10,607 | 0.0% | 0.00% | -50.0% |
| Q4 2022 | $121,768 | -7.8% | 10,607 | +1.6% | 0.00% | -33.3% |
| Q3 2022 | $132,000 | +23.4% | 10,444 | +3.7% | 0.00% | +50.0% |
| Q2 2022 | $107,000 | – | 10,074 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Burrage Capital Management LLC | 864,916 | $13,674,000 | 13.71% |
| Sarissa Capital Management LP | 4,261,000 | $67,366,000 | 5.36% |
| ORACLE INVESTMENT MANAGEMENT INC | 1,920,733 | $30,367,000 | 4.18% |
| HealthCor Management, L.P. | 3,248,100 | $51,352,000 | 2.05% |
| Parkman Healthcare Partners LLC | 351,961 | $5,565,000 | 1.22% |
| Bain Capital Public Equity Management II, LLC | 1,560,730 | $24,675,000 | 1.06% |
| Baker Brothers Advisors | 12,710,818 | $200,958,000 | 0.88% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 2,835,000 | $44,821,000 | 0.80% |
| Biondo Investment Advisors, LLC | 265,840 | $4,203,000 | 0.72% |
| EAM Global Investors LLC | 157,065 | $2,483,000 | 0.69% |